ClinicalTrials.gg
TerminatedNCT00507429FACTUpdated Jun 9, 2014Results posted

Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer

A Phase 2/3 interventional study of CA4P and paclitaxel in Anaplastic Thyroid Cancer, sponsored by Mateon Therapeutics. Terminated at 41 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-09.

Sponsored by Mateon Therapeutics · Phase 2/3, Interventional, and Treatment

How we know

Why this study was terminated
Low rate of subject accrual

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Thyroid Carcinoma, Anaplastic with a site in United States — 5 open to participants now, 14 under way, none of them phase 3. Thyroid Carcinoma, Anaplastic · United States.

Enrollment
8th of 47
80 · median 26
Started
2007
the only one that year
Phase 2/3
Only one
of the 50
Registered
14th of 50
by date

Among the 50 studies in Thyroid Carcinoma, Anaplastic with a site in United States, this one is the 8th largest by enrollment of the 47 interventional ones that give a count, is the only one that started in 2007, is the only one in phase 2/3, and was the 14th registered.

Thyroid Carcinoma, Anaplastic

87 studies on the registry are indexed under Thyroid Carcinoma, Anaplastic; 18 are open to participants now.

Browse Thyroid Carcinoma, Anaplastic studies →

Open to participants now

5 of the 50 studies in Thyroid Carcinoma, Anaplastic with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Thyroid Carcinoma, Anaplastic studies recruiting now, 14 (100%) set no upper age limit and none (0%) stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Thyroid Carcinoma, Anaplastic with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to determine the safety and efficacy of combretastatin combined with paclitaxel and carboplatin in the treatment of anaplastic thyroid cancer (ATC).

Read the detailed description

Anaplastic thyroid carcinoma (ATC) is a high-grade neoplasm, characterized by an aggressive clinical course with brief survival, and refractoriness to currently available local and systemic modalities of treatment. There is no standard therapy for ATC, and no randomized comparative trials have been known to be conducted in this disease. One potential strategy is to combine the anti-tumor activity of the vascular disrupting agent combretastatin with conventional cytotoxic agents. This study will compare the overall survival of ATC patients treated with the triplet combination of combretastatin, paclitaxel, and carboplatin compared with the doublet treatment of paclitaxel and carboplatin.

03

Conditions studied

  • Anaplastic Thyroid Cancer

Keywords

  • thyroid neoplasms
  • thyroid cancer
  • thyroid carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Anaplastic thyroid carcinoma or cytologically confirmed by a pathology review
  • to or progressed during or after therapy, or relapsed within 6 months following initial combined modality therapy (usually including systemic chemotherapy and radiation) for regionally advanced disease
  • Systemic therapy is limited to one chemotherapy regimen that is clearly administered contiguously, (i.e., in an uninterrupted primary therapeutic approach)
  • Prior radiation: 3 weeks must have elapsed since radiation and disease must be present beyond radiation ports
  • Minimum of 3 weeks must have elapsed from the time of last chemotherapy prior to the first dose of study drug
  • Patients with bulky thyroid/neck masses and/or suspicion of airway obstruction must undergo screening (indirect and direct laryngoscopy) to ensure patency of the trachea/airway prior to study enrollment and treatment
  • Performance Score less than or equal to 2
  • Adequate bone marrow reserve as evidenced by (ANC) greater than 1,500/microL, count greater than 75,000/microL.
  • Adequate renal function as evidenced by serum creatinine less than or equal to 2.0 mg/dL (less than 177 micromol/L)
  • Adequate hepatic function as evidenced by serum total less than 2X greater than the (ULN) (less than3X ULN in patients with liver ), (aspartate aminotransferase)/ALT (alanine aminotransferase) less than or equal to 3X the ULN for the local reference lab (less than or equal to 5X the ULN for patients with liver metastases)
  • No sequelae from any prior surgery or radiotherapy.

Exclusion criteria

Exclusion Criteria:

  • Tumors confined to the thyroid.
  • Clinically evident , including symptomatic involvement, evidence of cerebral edema by CT or MRI, radiographic evidence of progression of brain metastasis since definitive therapy, or continued requirement for
  • Patients who receive chemotherapy for disease after completion of a combined modality approach.
  • History of other than ATC except curatively treated basal cell carcinoma of the skin, cervical intra-epithelial neoplasia, or localized prostate cancer with a current PSA of less than 4.0 mg/dL or microg/L
  • Known to CA4P, paclitaxel or carboplatin, or any of their components
  • Receiving concurrent therapy or who have received investigational therapy for any indication within 28 days of the first scheduled day of dosing
  • Greater than Grade 2 peripheral neuropathy
  • History of prior cerebrovascular event, including
  • Uncontrolled hypertension (blood pressure greater than 150/100 mm Hg despite medication)
  • Symptomatic vascular disease (e.g. intermittent claudication)
  • History of unstable angina pectoris pattern, myocardial infarction (including non-Q wave MI) within the past 6 months, or Class III and IV congestive heart failure
  • History of torsade de pointes
  • Bradycardia (less than 60 b/m), heart block (excluding 1st degree block, being PR interval prolongation only), and congenital long syndrome
  • Any ventricular arrhythmias, or new ST segment elevation or depression or Q wave on
  • less than normal (i.e. less than 45%)
  • QTc prolongation greater than 450 ms
  • Requirement of any drugs known to prolong the QTc interval, including anti-arrhythmic medications
  • Potassium concentrations below 4.0 mEq/dL and magnesium concentrations below 1.8 mg/dL despite being on an electrolyte supplement
  • Requirement of any drugs known to prolong the QTc interval
  • History of solid organ transplant or bone marrow transplant
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Arm 1: CA4P + Carboplatin + paclitaxel

    Six 21-day cycles: CA4P (60 mg/m2 on Days 1, 8, 15), carboplatin (AUC 6) + paclitaxel (200 mg/m2) on Day 2

    Drug: CA4P

  • Active comparator
    Arm 2: Carboplatin + Paclitaxel

    Six 21-day cycles of Carboplatin (AUC 6) + paclitaxel (200 mg/m2) given on Day 1

    Drug: paclitaxel · Drug: carboplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Time frame: From randomization to date last known alive

Secondary outcomes

  1. To Determine Progression Free Survival

    Time frame: from randomization through end of study visit

  2. To Determine Percentage of 1 Year Survival

    Time frame: from randomization through end of study visit

07

Results

Posted Jun 9, 2014
Limitations and caveats
The study was to enroll 180 subjects. Enrollment was terminated early due to low accrual rate. Eighty subjects were enrolled.

Participant flow

Study truncated from 180 to 80 subjects. Subjects were enrolled from August 2007 through March 2010 at 40 worldwide, academic and local-regional clinical sites.

Treatment Phase
Participant flow — Treatment Phase
MilestoneArm 1, Active: CA4P + Carboplatin + PaclitaxelArm 2, Control: Carboplatin + Paclitaxel
Started5525
Completed187
Not completed3718
Withdrew: Disease progression125
Withdrew: Adverse event125
Withdrew: Withdrawal by subject33
Withdrew: Physician decision42
Withdrew: Other63
Maintenance Phase
Participant flow — Maintenance Phase
MilestoneArm 1, Active: CA4P + Carboplatin + PaclitaxelArm 2, Control: Carboplatin + Paclitaxel
Started160
Completed20
Not completed140
Withdrew: Progressive disease140

Outcome measures

PrimaryOverall Survival
Time frame:
From randomization to date last known alive
Reported as:
Median · months
Overall Survival
monthsArm 1, Active: CA4P + Carboplatin + PaclitaxelArm 2, Comparator: Carboplatin + Paclitaxel
Overall Survival5.2 (3.1 to 9.0)4.0 (2.8 to 6.2)
Statistical analysis
  • Arm 1, Active: CA4P + Carboplatin + Paclitaxel vs Arm 2, Comparator: Carboplatin + Paclitaxel · Log Rank · p = 0.223
SecondaryTo Determine Progression Free Survival
Time frame:
from randomization through end of study visit

Results for this outcome have not been posted.

SecondaryTo Determine Percentage of 1 Year Survival
Time frame:
from randomization through end of study visit
Reported as:
Number · percentage of participants
To Determine Percentage of 1 Year Survival
percentage of participantsArm 1, Active: CA4P + Carboplatin + PaclitaxelArm 2, Control: Carboplatin + Paclitaxel
To Determine Percentage of 1 Year Survival269

Adverse events

Collected over Adverse event data was collected over 2 years, 6 months. All serious adverse events were reported, regardless of relatedness. Adverse events occurring at a frequency of >/= 5% in either arm are reported, regardless of relatedness.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1, Active: CA4P + Carboplatin + Paclitaxel—21/51 (41.2%)50/51 (98%)
Arm 2, Comparator: Carboplatin + Paclitaxel—5/24 (20.8%)24/24 (100%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventArm 1, Active: CA4P + Carboplatin + PaclitaxelArm 2, Comparator: Carboplatin + Paclitaxel
BronchitisInfections and infestations5/512/24
AnemiaBlood and lymphatic system disorders1/512/24
DyspneaRespiratory, thoracic and mediastinal disorders4/511/24
Febrile NeutropeniaBlood and lymphatic system disorders3/510/24
HyponatremiaMetabolism and nutrition disorders0/511/24
Hypoxic encephalopathyNervous system disorders0/511/24
NeutropeniaBlood and lymphatic system disorders2/511/24
PneumoniaRespiratory, thoracic and mediastinal disorders2/511/24
Respiratory tract infectionInfections and infestations0/511/24
Sinus tachycardiaCardiac disorders0/511/24
Most frequent other events
Showing 10 of 75
Most frequent other events
EventArm 1, Active: CA4P + Carboplatin + PaclitaxelArm 2, Comparator: Carboplatin + Paclitaxel
NeutropeniaBlood and lymphatic system disorders30/517/24
AnemiaBlood and lymphatic system disorders20/5112/24
LeukopeniaBlood and lymphatic system disorders21/512/24
FatigueGeneral disorders18/517/24
HypertensionVascular disorders18/511/24
AlopeciaSkin and subcutaneous tissue disorders16/513/24
DiarrheaGastrointestinal disorders15/514/24
DyspeaRespiratory, thoracic and mediastinal disorders15/514/24
DysphagiaGastrointestinal disorders15/511/24
NauseaGastrointestinal disorders15/515/24

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm 1, Active: CA4P + Carboplatin + PaclitaxelArm 2, Control: Carboplatin + PaclitaxelTotal
<=18 years000
Between 18 and 65 years291443
>=65 years261137
Age, Continuous
Age, Continuous(years)Arm 1, Active: CA4P + Carboplatin + PaclitaxelArm 2, Control: Carboplatin + PaclitaxelTotal
Mean61.5 ± 10.7261.2 ± 10.5461.4 ± 10.60
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1, Active: CA4P + Carboplatin + PaclitaxelArm 2, Control: Carboplatin + PaclitaxelTotal
Female251843
Male30737
Region of Enrollment
Region of Enrollment(participants)Arm 1, Active: CA4P + Carboplatin + PaclitaxelArm 2, Control: Carboplatin + PaclitaxelTotal
Belarus112
United States20525
Poland516
Ukraine112
Romania101
Russian Federation213
Bulgaria303
Israel213
Italy13821
United Kingdom213
India5611
08

Study locations

41 sites
  • USC/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • Yale University, School of Medicine
    New Haven, Connecticut 06520, United States
  • Winship Cancer Institute, Emory University
    Atlanta, Georgia 30322, United States
  • Sidney Kimmel Comprehensive Cancer Care Center at John Hopkins
    Baltimore, Maryland 21231, United States
  • University of Minnesota Otolaryngology Department
    Minneapolis, Minnesota 55455, United States
  • Ireland Cancer Center/Division od Hematology
    Cleveland, Ohio 44106, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • University of Texas M.D. Anderson Cancer Center
    Houston, Texas 77030, United States
  • West Virginia University
    Morgantown, West Virginia 26506, United States
  • Belarus National Medical University
    Minsk, Belarus
  • Regional Oncology Dispensary with Inpatient Sector
    Plodiv, Bulgaria
  • Specialized Hospital for Active Treatment of Oncology
    Sofia, 1504, Bulgaria
  • Universtiy Multiprofile Hospital, ISUI, Clinic of Oncotherapy
    Sofia, Bulgaria
  • University Hospital, Cairo
    Cairo, Egypt
  • Mediciti Hospital
    Hyderabaad, Andhra Pradesh 500063, India
  • All India Institute of Medical Sciences
    New Delhi, Delhi 110029, India
  • Apollo Cancer Institute
    New Delhi, Delhi 110076, India
  • Kidwai Memorial Hospital
    Bangalore, Karnataka, India
  • Shirdi Sai Baba Cancer Hospital
    Manipal, Karnataka 576119, India
  • Tata Memorial Centre
    Mumbai, Maharashtra 400012, India
  • Ruby Hall Clinic
    Pune, Maharashtra 411011, India
  • Christian Medial College
    Vellore, Tamil Nadu, India
  • Telaviv Sourasky Medical Center, Head and Neck Service Division of Oncology
    Tel-Aviv, 64239, Israel
  • Lo Studio E la Cura
    Milano, 20133, Italy
  • INT Napoli Fondazione Pascale
    Napoli, Italy
  • Istituto Oncologico Veneto (IOV) - IRCCS
    Padova, 35128, Italy
  • Azienda Ospedaliero - Universitaria Pisana
    Pisa, 56124, Italy
  • Zaklad Medyczny Nuklearnej i Endykrynologii
    Gliwice, 44-101, Poland
  • Klinika Nowotworow Glowy i Szyji
    Warszawa, 02-781, Poland
  • Institutul Oncologic
    Cluj-Napoca, 400015, Romania
  • SC Meditech SRL
    Craiova, 200535, Romania
  • Centr of Medical Oncology
    Iasi, 700106, Romania
  • Clinical County Hospital Sibiu
    Sibiu, 550245, Romania
  • Emergency Clinical County Hospital "Sf. loan cel Nou"
    Suceava, 720237, Romania
  • City Clinical Oncology Dispensary
    Saint Petersburg, 198255, Russian Federation
  • Ukrainian Academy of Medical Science
    Lomonosova 33/43, Kiev 03022, Ukraine
  • Regional Clinical Oncology Dispensary
    Lvov, Ukraine
  • Beatson Oncology Centre, Gartnavel General Hospital
    Glasgow, Scotland G12 OYN, United Kingdom
  • Royal Marsden Hospital and Institute of Cancer Research
    London, SW3 6JJ, United Kingdom
  • Southampton Hospital Oncology Centre
    Southampton, United Kingdom
09

References and documents

Publications

  • Yeung SC, She M, Yang H, Pan J, Sun L, Chaplin D. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J Clin Endocrinol Metab. 2007 Aug;92(8):2902-9. doi: 10.1210/jc.2007-0027. Epub 2007 Jun 5. PubMed 17550961 ↗
  • Patel KN, Shaha AR. Poorly differentiated and anaplastic thyroid cancer. Cancer Control. 2006 Apr;13(2):119-28. doi: 10.1177/107327480601300206. PubMed 16735986 ↗
  • Ain KB. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid. 1998 Aug;8(8):715-26. doi: 10.1089/thy.1998.8.715. PubMed 9737368 ↗
  • De Crevoisier R, Baudin E, Bachelot A, Leboulleux S, Travagli JP, Caillou B, Schlumberger M. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1137-43. doi: 10.1016/j.ijrobp.2004.05.032. PubMed 15519785 ↗
  • Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer. 2004 Jun 15;100(12):2491-9. doi: 10.1002/cncr.20299. PubMed 15197790 ↗
  • Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res. 2006 Dec 15;66(24):11520-39. doi: 10.1158/0008-5472.CAN-06-2848. PubMed 17178843 ↗
  • Cooney MM, Savvides P, Agarwala SS, Wang D, Flick S, Bergant S, Bhatka S,Fu P, Subbiah V, Lavertu P, Ortiz J, and Remick S. Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma. J Clinical Oncology, 2006 Vol. 24, 5580.
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Oct 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2007
First posted
Jul 26, 2007
Start
Aug 2007
Primary completionActual
Oct 2011
CompletionActual
Nov 2011
Results first posted
Jun 9, 2014
Last update
Jun 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00507429
Lead sponsor
Mateon Therapeutics
Responsible party
Sponsor
First posted
Jul 26, 2007
Start date
Aug 2007
Primary completion
Oct 2011
Completion
Nov 2011
Results posted
Jun 9, 2014
Last update
Jun 9, 2014

Study contacts

Julie A. Sosa, MD, FACS
principal investigator · Yale University School of Medicine, New Haven, CT

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fosbretabulin tromethamine

Start the discussion